Brief: Longbio Pharma (Suzhou) Says FDA Approves Clinical Trial Application For LP-3 For Peanut Allergy
13/07/2026 02:43
BRIEF-Longbio Pharma (Suzhou) Says FDA Approves Clinical Trial Application For LP-3 For Peanut Allergy July 13 (Reuters) - LongBio Pharma (Suzhou) Co Ltd 1779.HK:
FDA APPROVES CLINICAL TRIAL APPLICATION FOR LP-3 FOR PEANUT ALLERGY
Further company coverage: 1779.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LongBio Pharma (Suzhou)
See all newsHK-listed LongBio Pharma jumps on inclusion in Stock Connect programs
Brief: Longbio Pharma (Suzhou) Says NMPA Accepts BLA For Lp-003 For Seasonal Allergic Rhinitis
Brief: Longbio Pharma (Suzhou) Says FDA Approves Clinical Trial Application For LP-3 For Peanut Allergy
Brief: Longbio Pharma (Suzhou)Says Phase III Trial Of LP-3 For Seasonal Allergic Rhinitis Meets Primary Endpoints
LongBio Pharma shines in Hong Kong debut; Lung Fung, Dajin fall